NASDAQ:KROS Keros Therapeutics Q3 2026 Earnings Results & Report $9.36 -0.09 (-0.95%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$9.32 -0.04 (-0.43%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Keros Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of $0.70 versus the -$0.96 consensus estimate, while revenue of $40.01 million topped the $14.76 million estimate by $25.25 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeAfter Market ClosesConference Call4:00 PM ET Keros Therapeutics EPS ResultsActual EPS$0.70Consensus EPS -$0.96Beat/MissBeat by +$1.66One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersKeros Therapeutics Revenue ResultsActual Revenue$40.01 millionExpected Revenue$14.76 millionBeat/MissBeat by +$25.25 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Keros Therapeutics Q3 2026 Earnings FAQ Did Keros Therapeutics beat earnings estimates for Q3 2026? Keros Therapeutics (NASDAQ:KROS) reported earnings of $0.70 per share for Q3 2026, beating the consensus estimate of -$0.96. The report was announced on Thursday, November 5, 2026. What was Keros Therapeutics' revenue for Q3 2026? Keros Therapeutics reported revenue of $40.01 million for Q3 2026, against a consensus estimate of $14.76 million. Keros Therapeutics Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), ANI Pharmaceuticals (ANIP) and Keros Therapeutics (KROS)November 7 at 8:28 PM | theglobeandmail.comKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsNovember 6 at 1:45 AM | markets.businessinsider.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th. | Behind the Markets (Ad)Keros Therapeutics (NASDAQ:KROS) Rating Lowered to "Strong Sell" at Wall Street ZenNovember 1, 2026 | americanbankingnews.comKeros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in PlaySeptember 30, 2026 | tipranks.comKeros Therapeutics Expects $20 Million Milestone Payment From TakedaSeptember 29, 2026 | finance.yahoo.comSee More Keros Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Keros Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your email. Email Address About Keros TherapeuticsKeros Therapeutics (NASDAQ:KROS) is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis. The company has also developed cibotercept (KER-012), an investigational therapy designed to modulate TGF-β family signaling for potential use in pulmonary arterial hypertension and other cardiovascular diseases. Founded in 2015 and headquartered in Lexington, Massachusetts, Keros conducts research and clinical-development activities primarily in the United States, with clinical programs potentially involving international trial sites. The company is led by founder and Chief Executive Officer Jasbir Seehra. Keros has not marketed an approved commercial product, and its therapies remain subject to clinical testing and regulatory review.View Keros Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Sandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
